相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study
Akiko Chiba et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
P. A. van Dam et al.
EJSO (2016)
Implementation of the 21-gene recurrence score test in the United States in 2011
Julie A. Lynch et al.
GENETICS IN MEDICINE (2016)
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment
Oleg Gluz et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer A Systematic Review and Meta-analysis
Laura M. Spring et al.
JAMA ONCOLOGY (2016)
Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age
Sandra M. Swain et al.
ADVANCES IN THERAPY (2015)
Neoadjuvant endocrine therapy for resectable breast cancer: A systematic review and meta-analysis
Frederico Leal et al.
BREAST (2015)
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score
Denise A. Yardley et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence
Amalia M. Issa et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2015)
Evaluating the 21-gene assay Recurrence ScoreA® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer
Takayuki Ueno et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2014)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Harry D. Bear et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Impact of the 21-Gene Recurrence Score Assay Compared With Standard Clinicopathologic Guidelines in Adjuvant Therapy Selection for Node-Negative, Estrogen Receptor-Positive Breast Cancer
Jessica F. Partin et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Effect of Oncotype DX Recurrence Score on Treatment Recommendations for Patients with Estrogen Receptor-Positive Early Stage Breast Cancer and Correlation with Estimation of Recurrence Risk by Breast Cancer Specialists
Jennifer E. Joh et al.
ONCOLOGIST (2011)
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
Marieke E. Straver et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy.
J. Parker et al.
CANCER RESEARCH (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients
Sadako Akashi-Tanaka et al.
BREAST (2009)
Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer
Luca Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Development of the 21-gene assay and its application in clinical practice and clinical trials
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients
Jenny C. Chang et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Impact of a Commercial Reference Laboratory Test Recurrence Score on Decision Making in Early-Stage Breast Cancer
Ruth Oratz et al.
JOURNAL OF ONCOLOGY PRACTICE (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy
L Gianni et al.
CLINICAL CANCER RESEARCH (2005)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Prediction of docetaxel response in human breast cancer by gene expression profiling
K Iwao-Koizumi et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27
HD Bear et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Meeting highlights:: Updated international expert consensus on the primary therapy of early breast cancer
A Goldhirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
